D-1300-2022 Class II Terminated

Recalled by Tolmar, Inc. — Fort Collins, CO

FDA drug recall D-1300-2022 was initiated by Tolmar, Inc. on Jul 11, 2022 and is designated Class II. Reason for recall: Failed Impurities/ degradation specifications: Out-of-Specification test results obtained for Unspecified Impurity Relative Retention Time The recall status is terminated (terminated Jun 22, 2023). Affected quantity: 1271 tubes.

Recall details

Product Type
Drugs
Report Date
Aug 10, 2022
Initiation Date
Jul 11, 2022
Termination Date
Jun 22, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1271 tubes

Product description

Naftifine Hydrochloride Gel, USP 1%, packaged in cartons with: a) Net Wt. 90g tube (NDC 0115-1510-48), b) Net Wt. 40g tube (NDC 0115-1510-63), c) Net Wt. 60g tube (NDC 0115-1510-58), Rx only, Manufactured by: Tolmar, Inc., Fort Collins, CO, 80526, Distributed by: Amneal Pharmaceuticals LLC, Bridgewater, NJ 08807

Reason for recall

Failed Impurities/ degradation specifications: Out-of-Specification test results obtained for Unspecified Impurity Relative Retention Time

Distribution pattern

distributed to 1 consignee in KY.

Code information

Lot #: a) 12070A, Exp 5/2023; 11801A, Exp 9/2022; b) 12386A, Exp 8/2023; 11800A, Exp 9/2022; c) 11940A, Exp 12/2022

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-1300-2022
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-1300-2022. Report a data issue: hello@regdatalab.com.